Skip to content
DataLookout
Menu

NCT06312826

Abbreviated MRI Using Gadoxetic Acid Versus Ultrasonography for Surveillance of Early-stage HCC in Patients at High Risk

StatusCompleted
PhaseNot applicable
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 11 words Show 6 more changesShow less
    • Trial completed
    • Primary completion date changed from estimate of Nov 2025 to Sep 15, 2025
    • Enrollment target: estimated 806 to confirmed 805
    • Study completion date changed from estimate of Dec 2027 to Mar 30, 2026
    • Secondary endpoints: 6 to 5
    • Publications: details revised at 1 of 1 entry
  2. Notable Lead sponsor: So Yeon Kim to Asan Medical Center
    • Secondary endpoints: 3 to 6
    • Collaborators expanded, about 1 word
    v3
  3. Notable Primary completion date: Dec 2024 to Nov 2025
    • Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 2 to 1
    v2
  4. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Detection rate of patients with early stage HCC
Timeframe: 6 months after the completion of the 2 surveillance rounds

Secondary (5)

False referral rate
Detection rate of patients with very early stage HCC
Detection rate of patients with all-stage HCC
Stage distribution at initial HCC diagnosis
Receipt of curative-intent treatment

Arms and interventions

US groupActive comparator

Subjects will be evaluated by two rounds of tests with abdominal US for the surveillance of HCC at intervals of 6 months.

AMRI groupExperimental

Subjects will be evaluated by two rounds of tests with AMRI for the surveillance of HCC at intervals of 6 months.

Procedures: Abdominal US, AMRI

Sites

1 site in 1 country

  • Asan Medical CenterSeoul, Songpa-gu, South Korea